Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.
Department of Infectious Diseases, Monash Medical Centre, Melbourne, Australia.
J Antimicrob Chemother. 2021 Feb 11;76(3):547-549. doi: 10.1093/jac/dkaa506.
The urgent need to develop effective therapeutics and disseminate information from clinical studies has led to data from clinical trials being made available by alternate methods prior to peer-reviewed publication, including press releases, social media and pre-print papers. While this allows clinicians more open access to these data, a trust has to be placed with the investigators releasing these data without the availability of scientifically rigorous peer review. The examples of results from trials studying dexamethasone and hydroxychloroquine for treatment of COVID-19 have had contrasting outcomes, including the potential for significant numbers of lives saved with the early release of results from the RECOVERY trial studying dexamethasone contrasting with unsubstantiated data being presented from trials studying hydroxychloroquine. Clinicians and researchers must maintain a healthy scepticism when reviewing results prior to peer-reviewed publication, but also consider when these opportunities may allow for early implementation of potentially lifesaving interventions for people infected with COVID-19.
迫切需要开发有效的治疗方法并传播临床研究信息，这导致临床试验数据通过替代方法在同行评审前发布，包括新闻稿、社交媒体和预印本论文。虽然这使得临床医生更容易获得这些数据，但必须相信发布这些数据的研究人员在没有经过科学严格的同行评审的情况下提供了这些数据。研究地塞米松和羟氯喹治疗 COVID-19 的试验结果的例子有截然不同的结果，包括早期发布研究地塞米松的恢复试验结果可能会挽救大量生命，而研究羟氯喹的试验则提出了未经证实的数据。临床医生和研究人员在审查同行评审前的结果时必须保持健康的怀疑态度，但也需要考虑这些机会何时可能允许对感染 COVID-19 的人早期实施潜在救生干预措施。
